Gland Pharma Limited (BSE: 543245 | NSE: GLAND) has reported a robust performance in its Q2 FY26 financial results, with revenue growth of 6% year-on-year, reaching ₹14.87 billion, and a 12% increase in Profit After Tax (PAT) to ₹1.84 billion. The results, disclosed on November 3, 2025, highlight the company's continued momentum, driven by strong performances in key markets such as the USA and Europe, which grew by 10% and 16%, respectively. Executive Chairman Srinivas Sadu emphasized the company's expectations for stronger momentum in the second half of the fiscal year, supported by new product launches and the recovery of Cenexi, a subsidiary of Gland Pharma.

The financial metrics for the first half of FY26 were equally impressive, showing a 7% increase in revenue and a remarkable 30% rise in PAT compared to the previous year. Gland Pharma's gross profit margin improved to 63%, while the EBITDA margin remained stable at 21% for the quarter. The company has also ramped up its R&D investments to ₹614 million, reflecting its commitment to innovation and new product development, which includes the launch of seven new molecules in the USA during the quarter.

Looking ahead, Gland Pharma is optimistic about its growth trajectory, particularly with its ongoing investments in capacity expansion and complex injectables. The company has filed six Abbreviated New Drug Applications (ANDAs) and has a solid pipeline for complex injectables, which it believes will be a key driver of long-term growth. Moreover, the company's Ready-to-Use (RTU) infusion bag portfolio addresses a significant market opportunity in the US, valued at approximately $659 million. This proactive approach underscores Gland Pharma's strategic focus on sustainable growth and value creation for its stakeholders.